S. aureus is the leading cause of skin and soft tissue infections such as abscesses (boils), furuncles, and cellulitis. The emergence of antibiotic-resistant S. aureus brings great challenges to treat S. aureus infections. With the years of experience in the field of antimicrobial agent discovery, Creative Biolabs is confident in offering the first-in-class anti-S. aureus drug discovery services for all global customers.
S. aureus is a gram-positive, sphere-shaped bacterium that belongs to the family of Staphylococcaceae. It is a common member of the human microbiota and is found in the upper respiratory tract and skin. This bacterium is a major cause of boils, furuncles, styes, impetigo and other superficial skin infections. Especially in persons debilitated by chronic illness, traumatic injury, burns or immunosuppression, S. aureus may cause more serious infections including pneumonia, deep abscesses, osteomyelitis, phlebitis, endocarditis, mastitis, and meningitis. S aureus has been regarded as a major cause of hospital-acquired infection of surgical wounds. It is established that about half a million patients in hospitals of the United States are infected with staphylococcus (mainly S. aureus) annually and up to 50,000 deaths each year are associated with S. aureus infections.
Fig.1 Scanning electron micrograph of S. aureus.
The major treatment for S. aureus infection is to administrate antibiotics. The penicillinase-resistant β-lactam antibiotic is the first-line treatment for S. aureus infection. This antibiotic inhibits the formation of peptidoglycan cross-linkages that is essential for bacterial cell walls, thereby killing bacterial cells. However, β-lactam antibiotic resistance in S. aureus is very common. Methicillin-resistant S. aureus (MRSA) is one of a number of greatly serious strains of S. aureus that is resistant to most β-lactam antibiotics. Vancomycin is a glycopeptide antibiotic that inhibits the synthesis of peptidoglycan, resulted in the destruction of bacterial cell walls. This antibiotic is commonly used to combat MRSA. At present, the medicines against antibiotic-resistant S. aureus are very limited and few new antibiotics have been developed. And there is no vaccine to combat staphylococcal infections. Hence, it is indispensable to develop more effective antimicrobials to combat S. aureus infection.
The enriched experience associated with state-of-the-art facilities, Creative Biolabs is a leading service provider that focuses on antimicrobials development for research and therapeutic use. Our scientists are confident in providing the most reliable and cost-effective solutions for the development of anti-S. aureus drugs, involved in target identification and validation, Hit identification, Hit to lead, Lead optimization, and IND enabling.
If you are interested in our services, please don’t hesitate to contact us for more information and a detailed quote.
For Research Use Only.
